doxapram 100mg/5ml solution for injection ampoules
synchrony pharma ltd - doxapram hydrochloride - solution for injection - 20mg/1ml
gemcitabine 1g powder for solution for infusion vials
synchrony pharma ltd - gemcitabine hydrochloride - powder for solution for infusion - 1gram
gemcitabine 200mg powder for solution for infusion vials
synchrony pharma ltd - gemcitabine hydrochloride - powder for solution for infusion - 200mg
ceftazidime 1g powder for solution for injection vials
synchrony pharma ltd - ceftazidime pentahydrate - powder for solution for injection - 1gram
ceftriaxone 1g powder for solution for injection vials
synchrony pharma ltd - ceftriaxone sodium - powder for solution for injection - 1gram
ceftriaxone 2g powder for solution for injection vials
synchrony pharma ltd - ceftriaxone sodium - powder for solution for injection - 2gram
ceftazidime 2g powder for solution for injection vials
synchrony pharma ltd - ceftazidime pentahydrate - powder for solution for injection - 2gram
meropenem 2g powder for solution for injection vials
synchrony pharma ltd - meropenem trihydrate - powder for solution for injection - 2gram
coralan 7.5 mg
medison pharma ltd - ivabradine as hydrochloride - film coated tablets - ivabradine as hydrochloride 7.5 mg - ivabradine - ivabradine - symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
coralan 5 mg
medison pharma ltd - ivabradine as hydrochloride - film coated tablets - ivabradine as hydrochloride 5 mg - ivabradine - ivabradine - symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.